Hematologic Malignancy
Chronic Lymphoproliferative Disorder of NK-Cells
CI-CAN-00004950Explore in graph →
HematologicNon-malignant3 active trials
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00004950Explore in graph →
Clinical trials
7 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05978141 | A Registry for People With T-cell Lymphoma | recruiting | — | 1,000 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT02863692 | Registry of the German CLL Study Group(CLL-Registry) | recruiting | — | 8,000 | German CLL Study GroupOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06530576 | Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia | recruiting | Phase 2 | 48 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06716658 | JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas | recruiting | Phase 2 | 48 | Institute of Hematology & Blood Diseases Hospital, China |
Data updated 22 days agoSource updated May 20, 2026source: clinicaltrials
| 1 |
| Nov 18, 2025 |
| clinicaltrials |
| NCT06530550 | PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas | recruiting | Phase 2 | 51 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07019766 | National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia(NICHE-LGLL) | recruiting | — | 9,999 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT04453345 | TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL | unknown | Phase 2 / Phase 3 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 1, 2020 | clinicaltrials |